Products

Mindpeak Breast
Mindpeak
Oncology AI
Mindpeak offers AI-driven image analysis solutions for breast pathology, aiming to standardize interpretation and reduce variability in biomarker analysis. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results.

See all 1 product →

About Mindpeak

Mindpeak is a pioneering healthcare AI company that develops cutting-edge artificial intelligence and deep learning solutions for digital pathology, primarily focused on enhancing cancer diagnostics. Their technology assists pathologists in routine diagnostics by automating the analysis of tissue images, including H&E, immunohistochemistry (IHC), and multiplex immunofluorescence (mIF) stains. This automation aims to provide faster, more accurate, and reproducible results, freeing specialists from tedious, repetitive tasks such as the quantification of cells or biomarkers, allowing them to concentrate on tasks requiring their unique human expertise.

The company’s AI algorithms are designed to extract precise, actionable insights from tissue images, supporting everything from subcellular biomarker quantification to predictive patient stratification. Mindpeak’s solutions are integrated into clinical workflows, with some of their AI-based diagnostic tools for breast cancer analysis (e.g., BreastIHC) already in routine clinical use in the US and EU. Beyond clinical labs, biopharmaceutical companies also leverage Mindpeak’s AI technology to predict the effectiveness of certain medications in cancer therapy and to enable targeted treatments, thereby bridging innovation and clinical impact in both routine diagnostics and biomarker development.

Focus Areas

AI-powered digital pathology cancer diagnostics automated tissue analysis biomarker quantification precision medicine deep learning oncology

Business Intelligence

Key InvestorsZEISS Ventures, InnoVentureFund, AI.FUND, European Innovation Council Fund, 11k Ventures, IFB Innovationsstarter, Cornelius Boersch, APEX Ventures
PartnershipsRoche, PathAI, Techcyte, Leica Biosystems, Epredia, AstraZeneca, Discovery Life Sciences, Gestalt Diagnostics, Paige, Sectra, PathPresenter, Crosscope, Smart in Media, Sysmex, Augmentiqs, Inspirata, Fraunhofer Mevis, Charité - Universitätsmedizin Berlin, Institut für Hämatopathologie Hamburg, Pathogenomics, Dermatologikum Hamburg, Labor Dr. Fenner & Kollegen, Tribun Health, Unilabs, BioReference Laboratories, Intermountain Healthcare, Universitätsklinikum Erlangen
TechnologyProprietary AI technology, deep learning models, explainable AI (xAI), hybrid deep learning technique, "IHC-first" foundation model, cloud-native (implied by integrations and global deployment)
FDA ClearancesUnknown cleared products (estimated)

What Physicians Need to Know

AI-Powered Digital Pathology
Mindpeak develops automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning, transforming tissue into high-dimensional data. Their solutions provide instant, pixel-level analysis of digital images of tissue samples.
Cancer Diagnostics & Automated Tissue Analysis
Mindpeak specializes in AI-driven cancer diagnostics, offering solutions for breast cancer (HER2, Ki-67, ER, PR, p53), lung cancer (PD-L1), and prostate cancer. Their tools automate tedious and repetitive tasks like cell and biomarker quantification, freeing up specialists.
Biomarker Quantification & Precision Medicine
The company enables the discovery of AI-driven biomarkers that guide targeted therapies and power precision medicine. Their AI decodes complex biological patterns invisible to the human eye, unlocking predictive signals for patient response to therapy.
Deep Learning & Oncology
Mindpeak utilizes proprietary clinical-grade deep learning architectures tailored to pathology, achieving results on par with human experts. Their focus is on oncology, providing solutions that enhance diagnostic confidence and efficiency in cancer care.
Key Differentiators
Mindpeak's key differentiators include '0-click' AI solutions that require no manual fine-tuning for various labs and staining protocols, ensuring immediate readiness for use. Their technology is built for clinical routine and regulatory oversight, with certifications reflecting a focus on safety, reproducibility, and global deployment. They offer robust, reproducible AI that performs in real laboratories and meets regulatory standards.
Technology Stack
Mindpeak's technology stack is built on state-of-the-art artificial intelligence and deep learning, specifically proprietary clinical-grade deep learning architectures. They leverage a 'hybrid deep learning technique' and an 'IHC-first' foundation model. Their solutions deliver instant, pixel-level analysis of digital images and can operate without cloud connectivity, ensuring data privacy and security.
Physician Tip

For physicians, Mindpeak's AI solutions offer several advantages. They can significantly reduce the time needed per case, leading to faster turnaround times for diagnoses. The AI provides reproducible results, minimizing inter-observer variability and supporting confident clinical decisions. By automating tedious tasks like cell and biomarker quantification, pathologists can focus their human expertise on more complex diagnostic challenges. The '0-click' nature of their solutions means minimal setup and immediate integration into existing workflows, enhancing lab productivity and diagnostic consistency. Furthermore, the combination of human experts with Mindpeak's AI can lead to accuracies beyond current standards.

Mindpeak's algorithms are designed for deep integration into the pathologist's workflow within partner software, aiming for a 'true 0-click-solution'. They also offer access through the Mindpeak AI Console. Mindpeak has established partnerships with leading digital pathology platforms and companies, including Gestalt Diagnostics (PathFlow platform), Paige (FullFocusu00ae viewer), Sectra (Amplifier Marketplace), Techcyte (Fusionu2122 Partner Program), and Leica Biosystems (Aperio HALO AP platform and Aperio AI Store). These collaborations ensure seamless workflow integration, streamlined data exchange, and expanded access to their AI solutions within various digital pathology ecosystems.

Products by Mindpeak

1 product in the directory

Mindpeak Breast
Mindpeak
Oncology AI
Mindpeak offers AI-driven image analysis solutions for breast pathology, aiming to standardize interpretation and reduce variability in biomarker analysis. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results.

Reviews & Opinions

No web reviews on file yet for Mindpeak. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Mindpeak.

Loading videos...

Videos load interactively. If none appear, search YouTube for Mindpeak →

View all on YouTube

Press & Coverage

GlobeNewswire
Mindpeak Secures First Patent for Advanced AI Method in Digital Pathology
Mindpeak has been granted its first patent for a novel method to train AI systems to accurately identify and classify cells in tissue samples for medical diagnosis, a significant milestone in advancing precision diagnostics in oncology. The patent is issued in 17 EU member states and validated in the UK, reinforcing Mindpeak's commitment to clinically reliable AI solutions.
2025-12
Leica Biosystems
Mindpeak Announces Global Reseller Agreement with Leica Biosystems to Expand Access to AI Pathology Solutions
Mindpeak and Leica Biosystems have entered a global reseller agreement, making Mindpeak's AI applications available within the Leica Biosystems digital pathology ecosystem. This collaboration aims to expand global access to AI-powered pathology analysis, integrating advanced AI into existing digital pathology workflows for greater efficiency and reproducibility.
2026-03
PR Newswire
Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
Discovery Life Sciences and Mindpeak have partnered to integrate AI-enabled digital image analysis into pathology services for global clinical trials, aiming to improve biomarker quantification and reduce inter-reader variability. This collaboration seeks to streamline trial processes, enhance data reproducibility, and support confident decisions in patient stratification and therapeutic development.
2026-03
Business Wire
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics
Epredia and Mindpeak have announced an EU distribution agreement for Mindpeak's AI-powered image recognition solutions in cancer diagnostics. This partnership aims to expand the availability of Mindpeak's technology across Europe.
2026-02
PathGroup
PathGroup Chooses Mindpeak to Power Its Digital Pathology Transformation
PathGroup has selected Mindpeak to enhance its digital pathology capabilities, integrating Mindpeak's AI solutions into its extensive diagnostic network. This collaboration will accelerate the adoption of scalable, interoperable AI solutions, starting with Mindpeak's Breast Suite and PD-L1 AI solutions, to improve diagnostic precision and consistency.
2025-11
Business Wire
Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology
Mindpeak has raised $15.3 million in a Series A funding round led by ZEISS Ventures and InnoVentureFund, with participation from AI.FUND and the European Innovation Council Fund. This investment will enable Mindpeak to expand the commercialization of its AI-powered pathology technologies globally and strengthen its product development roadmap.
2024-09
BioSpace
Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca
Mindpeak and AstraZeneca have launched an observational study to evaluate Mindpeak's Breast H&E AI software for primary breast cancer diagnosis in Brazil, Egypt, and Kenya. The collaboration aims to assess the transformative potential of AI in digital pathology to accelerate diagnosis and improve patient outcomes, especially in resource-limited areas.
2025-03
BioSpace
Mindpeak Partners with Roche to Enhance Digital Pathology with AI Integration
Mindpeak has announced a collaboration with Roche to integrate its AI algorithms with Roche's navifyu00ae Digital Pathology enterprise software. This partnership aims to improve diagnostic accuracy, streamline workflows, and advance personalized medicine in cancer diagnostics by reducing pre-analytical errors and enhancing efficiency.
2024-09

Frequently Asked Questions

Mindpeak offers a suite of AI-powered solutions for cancer diagnostics, including applications for breast cancer (HER2, Ki-67, ER/PR, p53), lung cancer (PD-L1), and prostate cancer. Their 'Pan-Tumor PD-L1 Suite' provides standardized PD-L1 quantification across various solid tumors, and they also offer H&E-based image analysis for prostate, breast, and macrodissection workflows.
Mindpeak's AI solutions undergo structured validation across multiple clinical sites and are continuously monitored in real-world environments to ensure reliability and reproducibility. They utilize a hybrid deep learning approach and focus on scalable 'Frontier Model AI' built for regulated environments, emphasizing validation and long-term integration.
Mindpeak operates within regulated clinical environments and maintains a formal quality management system. Their diagnostic products are CE-IVD certified, and the company operates under an ISO 13485 certified quality management system.
Mindpeak's software is designed to integrate seamlessly with established digital pathology infrastructures and image management systems, supporting scalable deployment across laboratory networks. They offer '0-click' solutions that integrate directly into partner software like Roche's navifyu00ae Digital Pathology and Leica Biosystems' Aperio digital pathology ecosystem, aiming to streamline workflows without disrupting routine clinical practice.
Mindpeak supports secure deployment models and complies with industry-standard data protection and IT security requirements. Their AI technology can deliver analysis without requiring cloud connectivity, offering data privacy and security for both clinical and research environments.
Mindpeak offers an AI-native training platform called peakAcademy, which supports standardized and reproducible biomarker assessment. They also collaborate with partners like Discovery Life Sciences to provide AI-enabled pathology workflows and pathologist training.
Mindpeak, founded in 2018, is a global innovator in AI-driven digital pathology solutions. They raised $15.3 million in a Series A funding round in September 2024, led by ZEISS Ventures and InnoVentureFund. Key partners include Roche, Leica Biosystems, PathGroup, Proscia, and Epredia, among others, facilitating the integration and distribution of their AI algorithms.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.